Literature DB >> 7227446

VP16-213 as a single agent in advanced testicular tumors.

B M Fitzharris, S B Kaye, S Saverymuttu, E S Newlands, A Barrett, M J Peckham, T J McElwain.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7227446     DOI: 10.1016/0014-2964(80)90178-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  20 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

3.  Testicular germ cell tumours--a model for a new approach to treatment of adult solid tumours.

Authors:  R T Oliver
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

4.  Clinical pharmacology of intracarotid etoposide.

Authors:  N Savaraj; L G Feun; K Lu; S Wallace; W S Fields; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.

Authors:  B A Ponder; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 6.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  A phase I trial of continuous infusion VP16-213 (etoposide).

Authors:  J Aisner; D A Van Echo; M Whitacre; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 8.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms.

Authors:  J Mortimer; R M Bukowski; J Montie; J S Hewlett; R B Livingston
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.